Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

reported in the New England Journal of Medicine that patients with COPD and type 2 inflammation who received the biologic agent dupilumab had fewer exacerbations, better lung function, and less severe ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Note: The chronological list does not include December approvals. 1. Dupixent (dupilumab) for chronic obstructive pulmonary disease: The monoclonal antibody, already approved for eczema ...

Chronic obstructive pulmonary disease (COPD ... to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease, shortly after ...

A highly effective drug for a debilitating lung disease is set to become the first new treatment for the condition in more ...

The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

Reuters Health Information, March 07, 2024 Dupilumab Earns FDA Priority Review for Add-On COPD Care The first new COPD treatment in a decade showed safety and effectiveness in a subset of patients ...

Medscape News UK, May 30, 2024 ATS 2024 Dupilumab Improves Outcomes in COPD With Type 2 Inflammation New trial confirmed safety and efficacy of a subcutaneous add-on therapy for uncontrolled COPD.

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...